Intravenous administration of high-dose vitamin C has recently attracted attention as a cancer therapy. High-dose vitamin C induces pro-oxidant effects and selectively kills cancer cells. However, the anticancer mechanisms of vitamin C are not fully understood. Here, we analyzed metabolic changes induced by vitamin C in MCF7 human breast adenocarcinoma and HT29 human colon cancer cells using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS). The metabolomic profiles of both cell lines were dramatically altered after exposure to cytotoxic concentrations of vitamin C. Levels of upstream metabolites in the glycolysis pathway and tricarboxylic acid (TCA) cycle were increased in both cell lines following treatment with vitamin C, while adenosine triphosphate (ATP) levels and adenylate energy charges were decreased concentration-dependently. Treatment with N-acetyl cysteine (NAC) and reduced glutathione (GSH) significantly inhibited vitamin C-induced cytotoxicity in MCF7 cells. NAC also suppressed vitamin C-dependent metabolic changes and NAD treatment prevented vitamin C-induced cell death. Collectively, our data suggests that vitamin C inhibited energy metabolism through NAD depletion, thereby inducing cancer cell death.
High-dose vitamin C treatment has a controversial history as a potential chemotherapeutic agent for cancer treatment1. A number of previous reports have suggested that high-dose vitamin C has anticancer effects2,3 while in other studies, it has shown no benefits in patients with cancer4,5. In view of these controversies, vitamin C treatment has recently been re-evaluated as a potential cancer therapy6,7,8,9,10. These analyses have revealed that high-dose vitamin C is more cytotoxic to cancer than it is to normal cells11. Moreover, vitamin C induces death of various types of cancer cells including mesothelioma, pancreatic and leukemia cells10,12,13. High-dose vitamin C suppressed tumor growth in animal models and tissue culture studies10,12 and, therefore, may indeed have applications as a novel treatment for various cancers.
High-dose vitamin C kills cancer cells by acting as a pro-drug, which delivers hydrogen peroxide (H2O2)8,10. Increased levels of reactive oxygen species (ROS) including H2O2 are thought to play an important role in the initiation and progression of cancer. Excessive levels of ROS are known to cause cellular damage including senescence via activation of protein kinase Cδ (PKCδ)11,14 and the release of cytochrome c from the mitochondria, leading to apoptosis15,16. Moreover, cellular ROS levels affect the redox status and metabolism17. H2O2 can change the ratio of oxidized glutathione (GSSG) and reduced (GSH) glutathione to a more oxidized state since H2O2 is reduced to water (H2O) by glutathione peroxidase (GPx)18. Previous reports also showed that vitamin C treatment induced cytotoxicity by adenosine triphosphate (ATP) depletion in some cancer cells6,12,19. Therefore, vitamin C-induced H2O2 may alter intracellular metabolism in cancer cells by disrupting the redox balance. However, the effects of vitamin C on metabolism, including glycolysis, the tricarboxylic acid (TCA) cycle and the pentose phosphate pathway (PPP), have not been clarified. Furthermore, the biological significance of vitamin C-induced metabolic alterations is still unknown.
Therefore, in this study, we sought to determine the effects of vitamin C on cancer cell metabolism using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS).
High-dose vitamin C-induced cytotoxicity in cancer cells
High-dose vitamin C has been reported to show significant anticancer effects in vitro and in vivo6,8. To confirm the effects of vitamin C on the survival of A431, Panc-1, HeLa, HT29 and MCF7 cells, we examined cell viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. The results showed that cell viability was decreased following exposure to high concentrations of vitamin C (3 or 10 mM) in all cancer cell lines (Fig. 1a). The HT29 cells were the least sensitive to vitamin C with a half-maximal inhibitory concentration (IC50) of 10 mM or more, followed by Panc-1, A-431, HeLa and MCF7 cells (IC50, 2.4 mM). These data suggests that high-dose vitamin C induced cytotoxic effects in cancer cells, albeit with varying efficacies.
Previous studies have reported that high-dose vitamin C induces H2O26,7,8,12. Therefore, we assessed the oxidative stress response in MCF7 cells treated with vitamin C by examining the expression of hemeoxygenase-1 (HO-1), a cellular oxidative stress marker, using quantitative real-time polymerase chain reaction (qPCR). HO-1 mRNA level in MCF7 cells significantly increased by vitamin C and H2O2 and this effect was suppressed by treatment with the antioxidant N-acetylcysteine (NAC, Fig. 1b). Furthermore, we investigated whether vitamin C induced cell death by generating H2O2 in MCF7 and HT29 cells. The antioxidants NAC and GSH attenuated the vitamin C-induced cytotoxicity in these cells (Fig. 1c), indicating that vitamin C-induced oxidative stress led to cancer cell death.
Metabolomic profiles of MCF7 cells treated with vitamin C
Next, we explored the effects of vitamin C on the metabolomic profile of MCF7 cancer cells using CE-TOFMS. The results revealed that following exposure to cytotoxic concentrations of vitamin C (≥1 mM) the levels of various metabolites were obviously altered in the MCF7 cells. Our analysis specifically revealed that the levels of the metabolites associated with the energy metabolism pathways examined, including those upstream of glycolysis, pentose phosphate pathway (PPP) and partial TCA cycle (citrate and cis-aconitate), were increased by the high-dose vitamin C (Fig. 2a). Conversely, the levels of metabolites downstream of glycolysis and the TCA cycle with the exception of citrate and cis-aconitate were decreased. ATP concentrations and adenylate energy charges were also decreased in a coordinated manner (Fig. 2b). These findings suggest that the high-dose vitamin C blocked the energy flux in glycolysis and the TCA cycle and consequently inhibited ATP production. Next, we examined whether the vitamin C-induced oxidative stress influenced the GSH redox balance. The levels of GSSG and GSH in the MCF7 cells were increased and decreased, respectively by vitamin C. In addition, the GSH/GSSG ratio was decreased at cytotoxic vitamin C concentrations and this effect was likely mediated by the associated generation of H2O2 generation, which may have affected the redox status of GSH (Fig. 2c). Furthermore, levels of amino acids, including Phe, Leu, Val, Ile, Lys, Trp, Ala, Tyr, Asp and Arg, in MCF7 cells were increased following vitamin C treatment (Supplementary Figure 1A). The effects of cytotoxic concentrations of vitamin C on the metabolomic profiles of the HT29 cells were similar (MCF7 cells ≥1 mM, HT29 cells 10 mM, Supplementary Figure 2A–D).
Effects of NAC on vitamin C-dependent reduction in energy metabolism in MCF7 cells
To examine whether the high-dose vitamin C-induced H2O2 inhibited energy metabolism, we analyzed the metabolomic profiles of MCF7 cells treated with vitamin C and the antioxidant NAC. The results revealed that most of the vitamin C-induced metabolic changes in glycolysis, the TCA cycle and the PPP were abolished by NAC treatment (Fig. 3a). In addition, ATP concentrations and adenylate energy charges were restored more by cotreatment with NAC than with vitamin C treatment alone (Fig. 3b). Interestingly, the metabolite profiles observed following vitamin C treatment were similar to those following H2O2 treatment (Fig. 3a). The changes in amino acid levels induced by vitamin C were also suppressed by NAC (Supplementary Figure 1B). These results suggest that vitamin C modulated energy metabolism by generating H2O2.
Vitamin C-induced H2O2 depleted nicotinamide adenine dinucleotide (NAD) in MCF7 cells
We found that vitamin C caused metabolic alterations in glycolysis and depleted ATP in MCF7 and HT29 cells (Fig. 2a,b, Supplementary Figure 2A and 2B). Intriguingly, the levels of the metabolites upstream of glycolysis in the MCF7 and HT29 cells were augmented following treatment with vitamin C while those downstream were reduced (Fig. 2a and Supplementary Figure 2A). Analysis of the metabolic profiles of the components of glycolysis suggested that the glycolytic flux between glyceraldehyde 3-phosphate (GAP) and D-glycerate 1,3-bisphosphate (1,3-BPG) mediated by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) may have been suppressed by vitamin C in the MCF7 and HT29 cells (Fig. 4a). To investigate whether metabolic changes induced by vitamin C were related to GAPDH, its expression was assessed using qPCR and was revealed to be unaffected by vitamin C or H2O2 treatment in MCF7 cells (Supplementary Figure 3). The treatment of U937 cells, which are derived from a human histiocytic lymphoma cell line, with H2O2, inactivates GAPDH via nicotinamide adenine dinucleotide (NAD) depletion17. Therefore, we examined the intracellular NAD levels in vitamin C-treated MCF7 cells treated and discovered the levels were decreased and this effect was reversed by NAC (Fig. 4b,c). These data suggest that high-dose vitamin C may inhibit glycolysis through NAD depletion. Moreover, we investigated whether vitamin C caused cell death through NAD depletion in MCF7 and HT29 cells. Our data showed that NAD suppressed the vitamin C-induced cell death in both cell lines (Fig. 4d). Taken together, these data suggest that vitamin C-induced oxidative stress inhibited the glycolytic flux by NAD depletion and consequently caused cell death.
In this study, we examined the effects of vitamin C on the metabolomic profiles of different cancer cells. Our data showed that high-dose vitamin C was cytotoxic in the cancer cell lines investigated and altered the levels of various metabolites. Therefore, these results suggest that vitamin C may indeed have applications as a potential anticancer therapeutic agent.
Numerous laboratories have reported that high-dose vitamin C treatment induces cell death by H2O2 generation6,10,12,16,20. In addition, H2O2 is involved in the maintenance of the redox status including the GSH/GSSG ratio and, is, therefore, expected to affect metabolism. In this study, we showed that levels of the upstream metabolites of glycolysis and TCA cycle were increased by vitamin C, while levels of those downstream were decreased. Additionally, ATP levels were decreased by vitamin C in the cancer cells tested, suggesting that vitamin C inhibited energy metabolism. We also found that cotreatment with NAC reversed the inhibitory effects of vitamin C on glycolysis, the TCA cycle and the PPP; these results confirmed that vitamin C disrupted energy metabolism by H2O2 generation. Finally, we found that NAD depletion was critical for the observed effects on glycolytic metabolism and subsequent induction of cell death. Therefore, our results showed that vitamin C-induced oxidative stress inhibited energy metabolism through NAD depletion and consequently caused cytotoxicity.
In this study, we found that the different cancer cell lines showed varying sensitivities to vitamin C and considered that this phenomenon may be regulated by multiple factors, such as redox system, transporter expression and hypoxia condition. For instance, we examined the cancer cell line death following treatment with H2O2 (data not shown) and discovered that its cytotoxicity was not correlated with that of vitamin C in these cell lines. Chen et al.6 reported no correlations between vitamin C-induced cell death and GSH, catalase, or GPx activities. Meanwhile, the vitamin C transporter was involved in the sensitivity of breast cancer cells to vitamin C21,22. Furthermore, hypoxic conditions (1% O2) suppressed the cytotoxicity of vitamin C more in 60 cancer cell lines than normoxic conditions (21% O2) did23.
In this study, we report the first demonstration of vitamin C-induced changes in metabolomic profiles. Recent studies have shown that cancer cell metabolism may be a possible target for therapy. Cancer cells reprogram their metabolic processes according to the tumor microenvironment or cancer progression24,25,26. Previous studies have also reported that oncogenic signals such as Ras and c-Myc activity regulate the expression of metabolic enzymes and thereby contribute to tumor development25,27,28. Moreover, cancer metabolism is characterized by abnormal energy production, known as the Warburg effect29,30,31,32,33. ATP generation in cancer cells shifts from oxidative phosphorylation to glycolysis, even under normoxic conditions. Therefore, glycolysis in cancer cells may be a potential target for cancer therapeutics. In our study, we found that vitamin C inhibited glycolysis by depleting NAD. Additionally, several reports have indicated that vitamin C therapy selectively kills cancer cells8,21. Therefore, since ATP production in cancer cells is more strongly dependent on glycolysis than it is in normal cells, the effects of vitamin C on survival may be more dramatic in cancer cells.
We found that vitamin C distinctly altered the pattern of the glycolytic metabolites. The GAPDH-mediated reaction between GAP and 1,3-BPG revealed that the upstream glycolytic metabolites were increased while those downstream decreased, in response to vitamin C treatment. GAPDH expression reportedly increased in several tumor types including prostate, breast and lung cancers34,35,36. Furthermore, GAPDH expression is upregulated via activation of the hypoxia-inducible factor (HIF-1) in breast cancer cells37. However, GAPDH expression in MCF7 cells was not increased following vitamin C treatment. Since the vitamin C-induced metabolic changes occurred within 1 h following treatment, the changes in the expression of metabolic enzymes may not be involved. On the other hand, vitamin C suppressed the NAD levels by generating H2O2 in MCF7 and HT29 cells and vitamin C-induced cell death was reversed by NAD supplementation in both cell lines. These data suggest that NAD depletion may trigger vitamin C-induced cell death in cancer cells. In addition, Chen et al.6 hypothesized that vitamin C-induced H2O2 causes DNA damage, leading to enhanced PARP activation, which may consume NAD and deplete ATP7. Our metabolomics studies supported this mechanism.
In conclusion, our findings suggest that vitamin C promoted cancer cell death by inhibiting energy metabolism via NAD depletion, induced by H2O2 generation. Further investigations are required to elucidate the specific mechanisms by which NAD depletion mediates the vitamin C-induced cytotoxicity. In addition, studies to confirm whether this pathway may be a potential target and thereby contribute to the improvement of cancer therapy would be expedient.
Regents and cell culture
Vitamin C, NAC, GSH and NAD were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human skin epidermoid carcinoma (A-431), human breast mammary gland adenocarcinoma (MCF7) and human colon colorectal adenocarcinoma (HT29) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Human cervix carcinoma (HeLa) cells were obtained from the Japanese Collection of Research Bioresources (Tokyo, Japan), while human pancreas adenocarcinoma (Panc-1) cells were purchased from the RIKEN BioResource Center (Tsukuba, Japan). All the cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Nissui Pharmaceuticals Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL streptomycin and 0.25 mg/mL amphotericin B at 37°C in a humidified atmosphere with 5% CO2.
Cell viability assay
The cell viability was measured using the MTT assay as follows. The cells (7.5 × 103) were seeded in each well of a 96-well plate and incubated for 24 h. Then, vitamin C was added and the cells were further incubated for 2 h, washed and then cultured for an additional 46 h in DMEM in the absence of vitamin C. The cells were pretreated with NAC, GSH and NAD 1 h prior to the incubation with vitamin C. Then, 50 μL of the MTT reagent (2 mg/mL in phosphate-buffered saline, PBS) was added to each well and the plates were incubated for an additional 2 h. The resulting formazan crystals were dissolved in 100 μL of dimethyl sulfoxide (DMSO) after the culture medium had been aspirate nm using a TECAN microplate reader with Magellan software (Männedorf, Switzerland).
RNA was extracted from vitamin C-treated MCF7 cells using TRIzol (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer’s protocol and 1 μg was reverse transcribed using a first-strand cDNA synthesis kit (ReverTra Ace α, Toyobo Co., Ltd., Osaka, Japan). The qPCR was performed using the SYBR premix Ex Taq (Takara, Shiga, Japan) on a StepOne Plus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Quantification was performed using the ΔΔCt method and RPL27 expression used as an internal reference. The melt curve analysis confirmed that all the qPCR products were generated in the form of double-stranded DNA. The primers used were as follows: HO-1, 5′-CGGGCCAGCAACAAAGTGCAAG-3′ (sense) and 5′-GTGTAAGGACCCATCGGAGAAG-3′ (antisense) and RPL27, 5′-CTGTCGTCAATAAGGATGTCT-3′ (sense) and 5′-CTTGTTCTTGCCTGTCTTGT-3′ (antisense).
Intracellular metabolites were measured in MCF7 and HT29 cells treated with vitamin C using CE-TOFMS (Agilent Technologies, Palo Alto, CA, USA) as previously described26,38. In brief, the MCF7 and HT29 cells were seeded at a density of 4 × 105 cells/well in 6-well plates. The cells were treated with vitamin C for 1 h and then washed twice with 5% mannitol. Then, 600 μL of methanol containing the internal standards (25 μM each of methionine sulfone, ethane sulfonic acid and D-Camphor-10-sulfonic acid) was added. The homogenate was mixed with 200 μL of Milli-Q water and 400 μL of chloroform. After centrifugation, the separated methanol-water layer was ultrafiltered using a Millipore 5-kDa cut-off filter to remove the proteins. The filtrate was lyophilized, dissolved in 25 μL of Milli-Q water and analyzed using CE-TOMS. The data obtained were analyzed using MasterHands39. The metabolite identities were determined by matching their m/z values and migration times with those of their standard compounds.
The data were analyzed using the GraphPad Prism v 5.0 software (La Jolla, CA, USA). The statistical analysis of the experimental results was performed using the one-way analysis of variance (ANOVA). Data are presented as means ± standard deviation (SD) and differences with P-values < 0.05 were considered statistically significant.
How to cite this article: Uetaki, M. et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci. Rep. 5, 13896; doi: 10.1038/srep13896 (2015).
Levine, M., Espey, M. G. & Chen, Q. Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic. Biol. Med. 47, 27–29, 10.1016/j.freeradbiomed.2009.04.001 (2009).
Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA 73, 3685–3689 (1976).
Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA. 75, 4538–4542 (1978).
Creagan, E. T. et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N. Engl. J. Med. 301, 687–690, 10.1056/NEJM197909273011303 (1979).
Moertel, C. G. et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N. Engl. J. Med. 312, 137–141, 10.1056/NEJM198501173120301 (1985).
Chen, Q. et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc. Natl. Acad. Sci. USA 102, 13604–13609, 10.1073/pnas.0506390102 (2005).
Chen, Q. et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA. 104, 8749–8754, 10.1073/pnas.0702854104 (2007).
Chen, Q. et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc. Natl. Acad. Sci. USA 105, 11105–11109, 10.1073/pnas.0804226105 (2008).
Du, J., Cullen, J. J. & Buettner, G. R. Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochim. Biophys. Acta 1826, 443–457, 10.1016/j.bbcan.2012.06.003 (2012).
Takemura, Y. et al. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem. Biophys. Res. Commun. 394, 249–253, 10.1016/j.bbrc.2010.02.012 (2010).
Takahashi, A. et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat. Cell Biol. 8, 1291–1297, 10.1038/ncb1491 (2006).
Du, J. et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin. Cancer Res. 16, 509–520, 10.1158/1078-0432.CCR-09-1713 (2010).
Roomi, M. W., House, D., Eckert-Maksic, M., Maksic, Z. B. & Tsao, C. S. Growth suppression of malignant leukemia cell line in vitro by ascorbic acid (vitamin C) and its derivatives. Cancer Lett. 122, 93–99 (1998).
Ramsey, M. R. & Sharpless, N. E. ROS as a tumour suppressor? Nat. Cell Biol. 8, 1213–1215 (2006).
Garrido, C. et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13, 1423–1433 (2006).
Han, D., Antunes, F., Canali, R., Rettori, D. & Cadenas, E. Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J. Biol. Chem. 278, 5557–5563, 10.1074/jbc.M210269200 (2003).
Colussi, C. et al. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J . 14, 2266–2276, 10.1096/fj.00-0074com (2000).
Buettner, G. R. Superoxide dismutase in redox biology: the roles of superoxide and hydrogen peroxide. Anticancer Agents Med. Chem . 11, 341–346 (2011).
Chen, P. et al. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23, 437–444, 10.1097/CAD.0b013e32834fd01f (2012).
Kim, J. et al. Enhanced antitumor activity of vitamin C via p53 in cancer cells. Free Radic. Biol. Med. 53, 1607–1615, 10.1016/j.freeradbiomed.2012.07.079 (2012).
Hong, S. W. et al. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32, 1508–1517, 10.1038/onc.2012.176 (2013).
Khurana, V., Kwatra, D., Pal, D. & Mitra, A. K. Molecular expression and functional activity of vitamin C specific transport system (SVCT2) in human breast cancer cells. Int. J. Pharm . 474, 14–24, 10.1016/j.ijpharm.2014.07.056 (2014).
Sinnberg, T. et al. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1alpha in the NCI60 cancer cell lines. J. Cell. Mol. Med. 18, 530–541, 10.1111/jcmm.12207 (2014).
Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85–95, 10.1038/nrc2981 (2011).
Soga, T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 104, 275–281, 10.1111/cas.12085 (2013).
Hirayama, A. et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69, 4918–4925, 10.1158/0008-5472.CAN-08-4806 (2009).
Irani, K. et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275, 1649–1652 (1997).
Vafa, O. et al. c-Myc can induce DNA damage, increase reactive oxygen species and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031–1044 (2002).
Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340–1344, 10.1126/science.1193494 (2010).
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033, 10.1126/science.1160809 (2009).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674, 10.1016/j.cell.2011.02.013 (2011).
Locasale, J. W. & Cantley, L. C. Metabolic flux and the regulation of mammalian cell growth. Cell metabolism 14, 443–451, 10.1016/j.cmet.2011.07.014 (2011).
Epner, D. E., Partin, A. W., Schalken, J. A., Isaacs, J. T. & Coffey, D. S. Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. Cancer Res. 53, 1995–1997 (1993).
Revillion, F., Pawlowski, V., Hornez, L. & Peyrat, J. P. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur. J. Cancer 36, 1038–1042 (2000).
Tokunaga, K. et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res. 47, 5616–5619 (1987).
Higashimura, Y. et al. Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. Arch. Biochem. Biophys. 509, 1–8, 10.1016/j.abb.2011.02.011 (2011).
Soga, T. et al. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal. Chem. 81, 6165–6174, 10.1021/ac900675k (2009).
Sugimoto, M., Wong, D. T., Hirayama, A., Soga, T. & Tomita, M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics: Official journal of the Metabolomic Society 6, 78–95, 10.1007/s11306-009-0178-y (2010).
The authors thank Drs. Kenjiro Kami and Mitsuhiro Kitagawa for their insightful discussions and technical advice. We also thank all the members of the metabolomics group at the Institute for Advanced Biosciences of the Keio University, Japan for their helpful suggestions. This study was supported by research funds from the Yamagata Prefectural Government and Tsuruoka City, Japan.
The authors declare no competing financial interests.
Electronic supplementary material
About this article
Cite this article
Uetaki, M., Tabata, S., Nakasuka, F. et al. Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress. Sci Rep 5, 13896 (2015). https://doi.org/10.1038/srep13896
Frontiers in Oncology (2020)
Current Pharmaceutical Biotechnology (2020)
A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
Integrative Cancer Therapies (2020)
The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies
Seminars in Cancer Biology (2020)
Enhanced Anticancer Effect of Adding Magnesium to Vitamin C Therapy: Inhibition of Hormetic Response by SVCT-2 Activation
Translational Oncology (2020)